These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18502785)

  • 1. Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males.
    Bode FJ; Stephan M; Suhling H; Pabst R; Straub RH; Raber KA; Bonin M; Nguyen HP; Riess O; Bauer A; Sjoberg C; Petersén A; von Hörsten S
    Hum Mol Genet; 2008 Sep; 17(17):2595-609. PubMed ID: 18502785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model.
    Bode FJ; Stephan M; Wiehager S; Nguyen HP; Björkqvist M; von Hörsten S; Bauer A; Petersén A
    Behav Brain Res; 2009 Dec; 205(1):175-82. PubMed ID: 19573560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease.
    Nguyen HP; Kobbe P; Rahne H; Wörpel T; Jäger B; Stephan M; Pabst R; Holzmann C; Riess O; Korr H; Kántor O; Petrasch-Parwez E; Wetzel R; Osmand A; von Hörsten S
    Hum Mol Genet; 2006 Nov; 15(21):3177-94. PubMed ID: 16984963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats.
    Kántor O; Temel Y; Holzmann C; Raber K; Nguyen HP; Cao C; Türkoglu HO; Rutten BP; Visser-Vandewalle V; Steinbusch HW; Blokland A; Korr H; Riess O; von Hörsten S; Schmitz C
    Neurobiol Dis; 2006 Jun; 22(3):538-47. PubMed ID: 16480885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.
    Cirillo G; Maggio N; Bianco MR; Vollono C; Sellitti S; Papa M
    Neurochem Int; 2010 Jan; 56(1):152-60. PubMed ID: 19799953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
    Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
    Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered emotional and motivational processing in the transgenic rat model for Huntington's disease.
    Faure A; Höhn S; Von Hörsten S; Delatour B; Raber K; Le Blanc P; Desvignes N; Doyère V; El Massioui N
    Neurobiol Learn Mem; 2011 Jan; 95(1):92-101. PubMed ID: 21111837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
    Tadros MG; Khalifa AE; Abdel-Naim AB; Arafa HM
    Pharmacol Biochem Behav; 2005 Nov; 82(3):574-82. PubMed ID: 16337998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
    Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
    Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
    Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and electrophysiological changes in the basal ganglia of transgenic Huntington's disease rats.
    Vlamings R; Benazzouz A; Chetrit J; Janssen ML; Kozan R; Visser-Vandewalle V; Steinbusch HW; von Hörsten S; Temel Y
    Neurobiol Dis; 2012 Dec; 48(3):488-94. PubMed ID: 22813864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17 beta-Estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats.
    Túnez I; Collado JA; Medina FJ; Peña J; Del C Muñoz M; Jimena I; Franco F; Rueda I; Feijóo M; Muntané J; Montilla P
    Neurochem Int; 2006 Apr; 48(5):367-73. PubMed ID: 16420966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.
    Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ
    Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation.
    Capetian P; Knoth R; Maciaczyk J; Pantazis G; Ditter M; Bokla L; Landwehrmeyer GB; Volk B; Nikkhah G
    Neuroscience; 2009 May; 160(3):661-75. PubMed ID: 19254752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.
    Rudinskiy N; Kaneko YA; Beesen AA; Gokce O; Régulier E; Déglon N; Luthi-Carter R
    J Neurochem; 2009 Oct; 111(2):460-72. PubMed ID: 19686238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
    Dhir A; Akula KK; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioning.
    Kells AP; Connor B
    Neurosci Lett; 2008 May; 436(3):326-30. PubMed ID: 18406531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice.
    Ehrman LA; Williams MT; Schaefer TL; Gudelsky GA; Reed TM; Fienberg AA; Greengard P; Vorhees CV
    Genes Brain Behav; 2006 Oct; 5(7):540-51. PubMed ID: 17010100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.